1. Home
  2. ARTL vs ALZN Comparison

ARTL vs ALZN Comparison

Compare ARTL & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • ALZN
  • Stock Information
  • Founded
  • ARTL 2011
  • ALZN 2016
  • Country
  • ARTL United States
  • ALZN United States
  • Employees
  • ARTL N/A
  • ALZN N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • ALZN Medicinal Chemicals and Botanical Products
  • Sector
  • ARTL Health Care
  • ALZN Health Care
  • Exchange
  • ARTL Nasdaq
  • ALZN Nasdaq
  • Market Cap
  • ARTL 3.1M
  • ALZN 2.6M
  • IPO Year
  • ARTL N/A
  • ALZN 2021
  • Fundamental
  • Price
  • ARTL $6.03
  • ALZN $3.03
  • Analyst Decision
  • ARTL Buy
  • ALZN Strong Buy
  • Analyst Count
  • ARTL 2
  • ALZN 1
  • Target Price
  • ARTL $30.00
  • ALZN $180.00
  • AVG Volume (30 Days)
  • ARTL 13.2K
  • ALZN 4.5M
  • Earning Date
  • ARTL 08-12-2025
  • ALZN 07-29-2025
  • Dividend Yield
  • ARTL N/A
  • ALZN N/A
  • EPS Growth
  • ARTL N/A
  • ALZN N/A
  • EPS
  • ARTL N/A
  • ALZN N/A
  • Revenue
  • ARTL N/A
  • ALZN N/A
  • Revenue This Year
  • ARTL N/A
  • ALZN $322.64
  • Revenue Next Year
  • ARTL N/A
  • ALZN N/A
  • P/E Ratio
  • ARTL N/A
  • ALZN N/A
  • Revenue Growth
  • ARTL N/A
  • ALZN N/A
  • 52 Week Low
  • ARTL $4.92
  • ALZN $2.90
  • 52 Week High
  • ARTL $9.30
  • ALZN $135.54
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 43.05
  • ALZN 37.30
  • Support Level
  • ARTL $6.20
  • ALZN $2.90
  • Resistance Level
  • ARTL $7.35
  • ALZN $3.07
  • Average True Range (ATR)
  • ARTL 0.45
  • ALZN 0.27
  • MACD
  • ARTL -0.09
  • ALZN 0.03
  • Stochastic Oscillator
  • ARTL 0.00
  • ALZN 6.16

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: